PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

Laura Martinez‐Verbo; Yoana Veselinova; Pere Llinàs‐Arias; Carlos A. García‐Prieto; Aleix Noguera‐Castells; Miguel L. Pato; Alberto Bueno-Costa; Ignacio Campillo‐Marcos; Lorea Villanueva; Aina Oliver‐Cáldes; Oriol Cardús; Sergi V. Salsench; Almudena García-Ortiz; Antonio Valeri; Elizabeta A. Rojas; Naroa Barrena; Norma C. Gutiérrez; Felipe Prósper; Xabier Agirre; Carlos Fernández de Larrea; Joaquín Martínez‐López; Gerardo Ferrer; Manel Esteller

doi:10.1038/s41375-024-02419-z

Article2024

Abstract P22: PVR (CD155) epigenetic status mediates adoptive cell therapy and anti-TIGIT response in Multiple Myeloma

Laura Martinez‐Verbo, Lorea Villanueva, Pere Llinàs‐Arias, Carlos A. García‐Prieto, David Piñeyro, Aina Oliver‐Cáldes, Almudena García-Ortiz, Antonio Valeri, Carlos Fernández de Larrea, Joaquín Martínez‐López, Gerardo Ferrer, Manel Esteller

Article2023

P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES

Laura Martinez‐Verbo, Lorea Villanueva, Pere Llinàs‐Arias, Carlos A. García‐Prieto, David Piñeyro, Aina Oliver‐Cáldes, Almudena García-Ortiz, Antonio Valeri, Carlos Fernández de Larrea, Joaquín Martínez‐López, Gerardo Ferrer, Manel Esteller

Article2020

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Ailin Lepletier, Jason Madore, Jake S. O’Donnell, Rebecca L. Johnston, Xian-Yang Li, Elizabeth S. McDonald, Elizabeth Ahern, Anna Kuchel, Melissa Eastgate, Sally‐Ann Pearson, Domenico Mallardo, Paolo A. Ascierto, Daniela Massi, Barbara Merelli, Mario Mandalà, James S. Wilmott, Alexander M. Menzies, Charles Leduc, J. C. A. Stagg, Bertrand Routy, Georgina V. Long, Richard A Scolyer, Tobias Bald,

Article2023

CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies

Laura Martinez‐Verbo, Lorea Villanueva, Pere Llinàs‐Arias, Carlos A. García‐Prieto, David Piñeyro, Aina Oliver‐Cáldes, Almudena García-Ortiz, Antonio Valeri, Carlos Fernández de Larrea, Joaquín Martínez‐López, Gerardo Ferrer, Manel Esteller

Article2025

Novel immunotherapy for multiple myeloma involving activation of plasmacytoid dendritic cells

Masayuki Kurimoto, Tomohiro Watanabe, Masatoshi Kudo

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

Discussion(0)

Related publications

Abstract P22: PVR (CD155) epigenetic status mediates adoptive cell therapy and anti-TIGIT response in Multiple Myeloma

P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies

Novel immunotherapy for multiple myeloma involving activation of plasmacytoid dendritic cells